New study tests Long-Term safety of apremilast in kids with rare inflammatory conditions

NCT ID NCT05767047

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 27 times

Summary

This study looks at the long-term safety of the drug apremilast in children aged 2 and older with oral ulcers from Behçet's disease, or aged 5 and older with juvenile psoriatic arthritis. About 48 kids who completed a previous study will take apremilast for up to 52 more weeks. Researchers will monitor side effects, growth, and development to ensure the drug remains safe over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BEHÇET'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • General Hospital of Thessaloniki Ippokrateio

    RECRUITING

    Thessaloniki, 54642, Greece

  • Hacettepe Universitesi Tip Fakultesi Hastanesi

    RECRUITING

    Ankara, 06100, Turkey (Türkiye)

  • Hospital Universitari i Politecnic La Fe

    RECRUITING

    Valencia, Valencia, 46026, Spain

  • Hospital Universitario Ramon y Cajal

    RECRUITING

    Madrid, 28034, Spain

  • Istanbul Universitesi Cerrahpasa Tip Fakultesi

    RECRUITING

    Istanbul, 34098, Turkey (Türkiye)

  • Meir Medical Center

    RECRUITING

    Kfar Saba, 4428164, Israel

  • Umraniye Egitim ve Arastirma Hastanesi

    RECRUITING

    Istanbul, 34764, Turkey (Türkiye)

Conditions

Explore the condition pages connected to this study.